HomeCompareTCAL vs ABBV

TCAL vs ABBV: Dividend Comparison 2026

TCAL yields 11.80% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $61.1K in total portfolio value· pulled ahead in Year 5
10 years
TCAL
TCAL
● Live price
11.80%
Share price
$22.23
Annual div
$2.62
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$43.6K
Annual income
$2,465.57
Full TCAL calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — TCAL vs ABBV

📍 ABBV pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTCALABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TCAL + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TCAL pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TCAL
Annual income on $10K today (after 15% tax)
$1,003.02/yr
After 10yr DRIP, annual income (after tax)
$2,095.73/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, ABBV beats the other by $19,771.14/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TCAL + ABBV for your $10,000?

TCAL: 50%ABBV: 50%
100% ABBV50/50100% TCAL
Portfolio after 10yr
$74.1K
Annual income
$14,095.64/yr
Blended yield
19.01%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

TCAL
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TCAL buys
0
ABBV buys
0
No recent congressional trades found for TCAL or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTCALABBV
Forward yield11.80%3.12%
Annual dividend / share$2.62$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$43.6K$104.7K
Annual income after 10y$2,465.57$25,725.73
Total dividends collected$18.1K$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TCAL vs ABBV ($10,000, DRIP)

YearTCAL PortfolioTCAL Income/yrABBV PortfolioABBV Income/yrGap
1$11,880$1,180.02$11,559$438.51+$321.00TCAL
2$14,022$1,310.16$13,494$640.86+$528.00TCAL
3$16,448$1,445.19$15,951$945.97+$497.00TCAL
4$19,184$1,584.40$19,152$1,413.89+$32.00TCAL
5← crossover$22,254$1,727.03$23,443$2,146.38$1.2KABBV
6$25,684$1,872.34$29,391$3,321.96$3.7KABBV
7$29,502$2,019.56$37,948$5,265.87$8.4KABBV
8$33,735$2,167.97$50,795$8,596.74$17.1KABBV
9$38,413$2,316.86$71,034$14,549.41$32.6KABBV
10$43,568$2,465.57$104,715$25,725.73$61.1KABBV

TCAL vs ABBV: Complete Analysis 2026

TCALStock

The fund seeks to provide regular distributions while aiming for capital preservation with potential for capital appreciation.

Full TCAL Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this TCAL vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TCAL vs SCHDTCAL vs JEPITCAL vs OTCAL vs KOTCAL vs MAINTCAL vs JNJTCAL vs MRKTCAL vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.